Latest news with #YongweiHu
Yahoo
13-05-2025
- Business
- Yahoo
BON Debuts Groundbreaking Broccoli-Derived Sleep Wellness Line, Reshaping the Sleep Health Market through Innovative Technology
XI'AN, China, May 13, 2025 (GLOBE NEWSWIRE) -- BON Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), a leading provider of bio-ingredient solutions for the natural health and personal care sectors, today announced the groundbreaking launch of its sleep health product series. Developed using the proprietary 'Glucoraphanin-Myrosinase' delivery system (patent-pending), the Company intends for this product to dramatically enhance the bio-activity (the extent to which something is absorbed and utilized by the body) of glucoraphanin, a vital bio-active compound in broccoli and will be launched under the Company's owned brand. Broccoli, a nutrient-rich superfood, contains glucoraphanin, a key bio-active compound that undergoes metabolic conversion into sulforaphane in the human body. Sulforaphane has been linked to multiple health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects. However, the enzymatic conversion of glucoraphanin into its active form, sulforaphane, is inefficient making it difficult for the body to fully utilize the health benefits of broccoli. This creates challenges for nutritional utilization and commercial application. The Company believes its patent-pending 'Glucoraphanin-Myrosinase' represents an innovative biotechnological delivery system. By ensuring optimal enzymatic activation in the body, it achieves an advanced conversion efficiency of bio-active sulforaphane. This system is intended to help resolve fundamental bio-availability challenges. With its precision-driven design, easy usage, and consumer-friendly format, the Company believes this advancement holds transformative potentials through re-positioning glucoraphanin-sulforaphane in the health and wellness market, which will allow the Company to capitalize on potential revenue opportunities. 'BON's new sleep health products aim to outperform conventional formulations with superior bio-availability, enhanced biological potency, and consumer-friendly usability,' Mr. Yongwei Hu, Chairman and CEO of BON, emphasized. 'Our Glucoraphanin-Myrosinase delivery system aims to combine scientific rigor with commercial potential. It addresses critical unmet needs in sleep health and, we believe, is primed for rapid market adoption. We anticipate that this series of new products will achieve market expansion, thereby bolstering the Company's business growth. Furthermore, the proliferation of this product category is intended to profoundly alter the dynamics of the sleep health market.' About Bon Natural Life Limited ("BON") BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at For more information, please contact: Cindy Liu | IR Email: bonnatural@ Safe Harbor Statement This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes", "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking in to access your portfolio
Yahoo
11-04-2025
- Business
- Yahoo
BON Announces Apple Polyphenol Commercial Order Signed
XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply agreement worth $12M with Shanghai Yunsheng, China's premier functional ingredients distributor, to co-develop next-generation apple polyphenol-infused health solutions. The partnership leverages BON's patented extraction technology to deliver science-backed formulations combining antioxidant-rich apple polyphenols with plant-based proteins, proven to support weight management and metabolic health. Protein supplements have evolved into a mainstream wellness staple over decades, cementing their role in fitness regimens, immune health protocols, and longevity-focused nutrition. The strategic incorporation of apple polyphenols into these formulations now unlocks targeted benefits-clinically validated lipid management, enhanced body composition outcomes, and mitigation of age-related muscle atrophy-positioning this innovation at the convergence of proven demand and novel functionality. Early market validation proves compelling-comparable apple polyphenol blends have achieved blockbuster status since launch, selling over half a million units monthly and generating $40M in recurring revenue. Industry analysts note this reflects growing consumer willingness to pay premium pricing for validated "nutraceutical crossover" products. 'As one of the world's premier apple polyphenol suppliers, we're leveraging our vertically integrated supply chain to dominate this high-growth niche,' said Yongwei Hu, Chairman and CEO of the Company, 'the company anticipates compounding revenue streams from the ingredient's dual applications-both as a standalone nutraceutical and as a functional food additive-while maintaining disciplined margin control to maximize shareholder returns.' About Bon Natural Life Limited ("BON") BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at For more information, please contact: Cindy Liu | IR Email: bonnatural@ Safe Harbor Statement This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking in to access your portfolio
Associated Press
25-03-2025
- Business
- Associated Press
BON Announces Revolutionary Postbiotic Blood Sugar Solution Nears Patent Launch
Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced on Thursday, March 20 that a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar was gearing up for release. Yongwei Hu, CEO & Chairman of BON, said 'Backed by a robust IP strategy, BON is aggressively pursuing global patent protection. Over the next two years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal.' As China pushes its Healthy China 2030 agenda, the health industry is riding a sustained growth wave. According to iiMedia Data, a local authoritative third-party data monitoring institution, the market size of China's health food products industry in 2023 exceeded 328 billion RMB ($45.5 billion), and is expected to reach 423.7 billion RMB ($58.8 billion) by 2027. Among them, vitamins and dietary supplements (VDS) account for over half of the total market. While China's VDS spending per capita remains 22% of the U.S. levels, analysts project accelerated demand driven by aging demographics and preventive healthcare trends. BON is positioning itself at the forefront of this fastest-growing industry. A strategic partnership built on March 9 with China's agricultural giant Sanzhuliang Group Co., Ltd. signals BON's ambition to bridge farming and biotech. The collaboration, facilitated by the Listed Companies Division of Commercial Culture Association of China, will focus on biotech innovation, functional food R&D, smart agriculture, industry standards, and more. An expert workstation under the Division was launched at BON's headquarters to advance digital transformation and promote traditional Chinese medicine globally. The Company's recent stock surge underscores investor confidence in its leadership in China's trillion-dollar functional food market. On Friday, March 14, BON stock skyrocketed over 300%, triggering multiple trading halts. Days later, BON priced a best efforts offering of $12 million, before deducting placement agent fees and other estimated expenses payable by the Company. BON intends to use the net proceeds from this offering for R&D, product expansion, global marketing and other corporate purposes. As one of the few suppliers of stachyose, an extract from stachy affinis and also a prebiotic that can promote human intestinal health, BON has built an international footprint with products sold across Asia, the U.S., and the EU. Its portfolio includes stachyose, apple polyphenols, broccoli extracts, and proprietary formulations like probiotic powder drinks and micro-eco repair shampoos. About Bon Natural Life Limited ('BON') Country: China
